Danske Bank A S Purchases Shares of 32,429 West Pharmaceutical Services, Inc. $WST

Danske Bank A S acquired a new stake in West Pharmaceutical Services, Inc. (NYSE:WST) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm acquired 32,429 shares of the medical instruments supplier’s stock, valued at approximately $11,642,000.

Other institutional investors also recently modified their holdings of the company. Avalon Trust Co acquired a new stake in West Pharmaceutical Services in the 2nd quarter valued at about $28,000. Elyxium Wealth LLC acquired a new position in West Pharmaceutical Services during the fourth quarter worth approximately $25,000. Bayban bought a new stake in West Pharmaceutical Services in the fourth quarter valued at approximately $27,000. Private Trust Co. NA lifted its position in shares of West Pharmaceutical Services by 156.4% in the fourth quarter. Private Trust Co. NA now owns 100 shares of the medical instruments supplier’s stock valued at $28,000 after buying an additional 61 shares during the last quarter. Finally, DV Equities LLC acquired a new stake in shares of West Pharmaceutical Services in the fourth quarter valued at approximately $28,000. 93.90% of the stock is currently owned by institutional investors and hedge funds.

West Pharmaceutical Services Stock Performance

Shares of NYSE:WST opened at $352.94 on Friday. West Pharmaceutical Services, Inc. has a 12-month low of $223.83 and a 12-month high of $386.00. The company’s 50 day moving average price is $348.61 and its two-hundred day moving average price is $299.75. The firm has a market cap of $24.84 billion, a PE ratio of 45.19, a PEG ratio of 2.47 and a beta of 1.15. The company has a quick ratio of 2.12, a current ratio of 2.82 and a debt-to-equity ratio of 0.07.

West Pharmaceutical Services (NYSE:WST) last released its quarterly earnings results on Thursday, July 23rd. The medical instruments supplier reported $2.37 earnings per share for the quarter, beating analysts’ consensus estimates of $2.08 by $0.29. The company had revenue of $872.30 million during the quarter, compared to the consensus estimate of $839.98 million. West Pharmaceutical Services had a net margin of 16.98% and a return on equity of 20.11%. The firm’s quarterly revenue was up 13.8% on a year-over-year basis. During the same period in the previous year, the business earned $1.84 earnings per share. West Pharmaceutical Services has set its Q3 2026 guidance at 2.140-2.240 EPS and its FY 2026 guidance at 8.850-9.050 EPS. Equities research analysts predict that West Pharmaceutical Services, Inc. will post 8.93 earnings per share for the current year.

West Pharmaceutical Services Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, August 5th. Shareholders of record on Wednesday, July 29th were issued a $0.22 dividend. The ex-dividend date of this dividend was Wednesday, July 29th. This represents a $0.88 annualized dividend and a yield of 0.2%. West Pharmaceutical Services’s payout ratio is currently 11.27%.

Analyst Ratings Changes

A number of research analysts recently weighed in on WST shares. Morgan Stanley boosted their target price on West Pharmaceutical Services from $325.00 to $365.00 and gave the stock an “equal weight” rating in a report on Thursday, July 9th. Wolfe Research started coverage on shares of West Pharmaceutical Services in a research report on Monday, June 1st. They set an “outperform” rating and a $375.00 price objective for the company. Stephens reiterated an “overweight” rating and issued a $360.00 price objective on shares of West Pharmaceutical Services in a report on Tuesday, June 2nd. Zacks Research lowered shares of West Pharmaceutical Services from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, August 12th. Finally, Barclays upgraded shares of West Pharmaceutical Services from an “equal weight” rating to an “overweight” rating and raised their target price for the stock from $310.00 to $400.00 in a research note on Tuesday, June 9th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $368.08.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.